Prebiopsy PSA Velocity Not Reliable Predictor of Prostate Cancer Diagnosis, Gleason Score, Tumor Location, or Cancer Volume After TTMB

Urology

Volumn 74, Issue 1, 2009, Pages 171-176

  Bittner, Nathan ^a   Merrick, Gregory S ^b   Andreini, Hugo ^c   Taubenslag, Walter ^c   Allen, Zachariah A ^b   Butler, Wayne M ^b   Anderson, Richard L ^b   Adamovich, Edward ^c   Wallner, Kent E ^d  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b WHEELING JESUIT UNIVERSITY   (United States)

^c WHEELING HOSPITAL   (United States)

^d DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; TUMOR LOCALIZATION; TUMOR VOLUME;

BIOPSY, NEEDLE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 67649228679     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.12.013     Document Type: Article

References (21)

1. Etzioni R., Ankerst D., Weiss N., et al. Is prostate-specific antigen velocity useful in early detection of prostate cancer?. A critical appraisal of the evidence. J Natl Cancer Inst 99 (2007) 1510-1515
2. Perrin P. PSA velocity and prostate cancer detection: the absence of evidence is not the evidence of absence. Eur Urol 49 (2006) 418-419
3. Roobol M., Kranse R., de Koning H., et al. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (Rotterdam). Urology 63 (2004) 309-313
4. Schröder F., Roobol M., van der Kwast, et al. Does PSA velocity predict prostate cancer in pre-screened populations?. Eur Urol 49 (2006) 460-465
5. D'Amico A., Chen M., Roehl K., et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351 (2004) 125-135
6. D'Amico A., Renshaw A., Sussman B., et al. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 294 (2005) 440-447
7. Punglia R., Cullen J., McLeod D., et al. Prostate-specific antigen velocity and the detection of Gleason score 7-10 prostate cancer. Cancer 110 (2007) 1973-1978
8. Carter H., Ferrucci L., Ketterman A., et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 98 (2006) 1521-1527
9. Loeb S., Roehl K., Xiaoying Y., et al. Use of prostate-specific antigen velocity to follow up patients with isolated high-grade prostatic intraepithelial neoplasia on prostate biopsy. Urology 69 (2007) 108-112
10. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. http://www.nccn.org/professionals/physician_gls/about.asp Accessed May 15, 2008.
11. Stewart C., Leibovich B., Weaver A., et al. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol 166 (2001) 86-92
12. Rabbani F., Stroumbakis N., Kava B., et al. Incidence and clinical significance of false-negative sextant prostate biopsies. J Urol 159 (1998) 1247-1250
13. Eskew L., Bare R., and McCullough D.L. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 157 (1997) 199-203
14. Presti J., Chang J., Bhargava V., et al. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. J Urol 163 (2000) 163-166
15. Merrick G.S., Gutman S., Andreini H., et al. Prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy. Eur Urol 52 (2007) 715-724
16. Meng M., Shinohara K., and Grossfeld G. Significance of high-grade prostatic intraepithelial neoplasia on prostate biopsy. Urol Oncol 21 (2003) 145-151
17. Merrick G., Taubenslag W., Andreini H., et al. The morbidity of transperineal template-guided prostate mapping biopsy. BJU Int 101 (2008) 1524-1529
18. Eggener S., Yossepowitch O., Roehl K., et al. Relationship of prostate-specific antigen velocity to histologic findings in a prostate cancer screening program. Urology 71 (2008) 1016-1019
19. Stav K., Leibovici D., Sandbank J., et al. Saturation prostate biopsy in high risk patients after multiple previous negative biopsies. Urology 71 (2008) 399-403
20. Nakanishi H., Wang X., Ochiai A., et al. A nomogram for predicting low-volume/low-grade prostate cancer: a tool in selecting patients for active surveillance. Cancer 110 (2007) 2441-2447
21. Ashley R., Inman B., Routh J., et al. Reassessing the diagnostic yield of saturation biopsy of the prostate. Eur Urol 53 (2008) 976-981